Foundayo vs Zepbound: The New Pill vs the Strongest Shot

If you’re choosing between Foundayo, the new oral weight-loss drug, and Zepbound, the most effective injectable, the tradeoff comes down to convenience versus raw results. Foundayo (orforglipron) is a once-daily pill that produced about 12% average weight loss in its trials. Zepbound (tirzepatide) is a weekly injection that produced about 21%. So Zepbound wins on weight loss by a wide margin, while Foundayo wins on ease: no needles, no refrigeration, take it any time of day. For someone who’d never start an injection, Foundayo opens a door. For someone whose priority is maximum weight loss, Zepbound is still the stronger tool.

Here’s the full comparison so you can decide which side of that tradeoff you’re on.

The core difference: efficacy

These two drugs are not close on weight loss, and that’s the most important fact to get straight. Foundayo’s approval rested on Eli Lilly’s ATTAIN program, where the highest dose produced roughly 12% average weight loss over 72 weeks. Zepbound’s trials have repeatedly landed near or above 20%. In SURMOUNT-3, where participants first lost weight through intensive lifestyle changes and then added tirzepatide, the medication drove an additional 18% on top of that, for total losses around 25% (Wadden et al., Nature Medicine 2023).

Foundayo’s efficacy sits closer to first-generation injectable semaglutide than to tirzepatide. Lilly’s own leadership has said Zepbound remains more effective, and the trial numbers back that up. The pitch for Foundayo was never that it beats the shots; it’s that a daily oral reaches people the shots don’t.

How they differ at a glance

Cost: closer than the efficacy gap

On price, the two are nearer than you might expect. Foundayo’s self-pay cash price through LillyDirect runs $149 a month at the lowest dose and up to $349 at the highest. Zepbound’s self-pay vials through LillyDirect run $299 (2.5 mg), $399 (5 to 10 mg), and $449 (12.5 to 15 mg) a month. So Foundayo is somewhat cheaper at maintenance, but not dramatically.

Both drugs drop to about $25 a month with commercial insurance that covers them, and both are included in the Medicare GLP-1 Bridge at about $50 a month for eligible Part D members starting July 1, 2026. The dollar difference between them is real but modest. The weight-loss difference is the bigger lever.

Convenience and the practical fine print

Foundayo’s appeal is genuine flexibility. It’s a small-molecule, non-peptide drug, which lets it be taken any time of day with or without food, and it doesn’t need refrigeration. That matters for travel, for people with needle aversion, and for anyone who’d rather not build a weekly injection into their routine. Our Foundayo dosing guide covers the week-by-week titration and what to expect.

A few cautions apply to both. Each carries a boxed warning for thyroid C-cell tumors and isn’t for people with a personal or family history of medullary thyroid cancer or MEN-2. Both produce gastrointestinal side effects, mainly nausea, especially during dose increases. Foundayo can also reduce how well oral birth control works, so a backup method is advised for a stretch after starting and after each dose step-up.

One thing that doesn’t differ: you can’t legitimately get a compounded version of Foundayo. Orforglipron is a small molecule that has never been on the FDA shortage list, so any site selling compounded orforglipron should be treated as suspect. Tirzepatide, by contrast, can still be compounded by licensed pharmacies in specific clinical situations, which is part of why cash-pay routes to tirzepatide exist.

Which should you choose?

Consider a scenario where two people are deciding. The first has a strong needle phobia and a moderate amount of weight to lose; for them, a pill they’ll actually take beats a stronger drug they’ll avoid, so Foundayo makes sense. The second has a higher starting weight, wants the most effective option available, and is comfortable with a weekly injection; for them, Zepbound’s efficacy advantage is hard to pass up.

If cost is the deciding factor and you’re paying cash, it’s worth comparing the brand routes against compounded options. Our guide to the cheapest ways to get GLP-1 medications lays out the landscape, and our 2026 comparison of the leading weight-loss medications ranks them on results and value.

TrimRx is a cash-pay telehealth program that connects you with licensed providers for physician-prescribed semaglutide and tirzepatide, with monthly pricing across the program’s medications running from $179 to $1,579 depending on the medication and plan. TrimRx works with the injectable molecules, including tirzepatide, rather than orforglipron, so it’s a route to the stronger option without the brand-name retail price. To see what fits, the free assessment quiz takes a few minutes and routes your information to a licensed provider for review.

This article is for general educational purposes and isn’t medical advice. Both medications carry a boxed warning and aren’t appropriate for everyone. Drug pricing and programs change frequently, so verify current details with LillyDirect, your insurer, and your prescriber before making decisions.